Instil Bio is a biotechnology company focused on identifying and advancing therapeutic opportunities. The company's strategy involves pursuing acquisitions or in-licensing of novel therapeutic candidates for diseases with significant unmet medical need. Its wholly owned subsidiary, Axion Bio, previously developed AXN-2510, a bispecific antibody targeting programmed death-ligand 1 and vascular endothelial growth factors for solid tumor cancers, which was in-licensed from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in 2024 before development was discontinued in 2026. Prior to this, the company focused on cell therapies, including a proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for cancer treatment. Instil Bio operates in the oncology sector, targeting solid tumors and other conditions, and relies on intellectual property protection and regulatory approvals from agencies such as the U.S. Food and Drug Administration for its product candidates.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage instilbio.com
Sector Healthcare IR page ir.instilbio.com
Tags
oncology, bispecific antibodies, cell therapy, tumor infiltrating lymphocytes, immuno-oncology, solid tumors, drug discovery, in-licensing, Axion Bio, AXN-2510, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., CoStAR, TIL cell therapy
Press page —

Metrics

Valuation  
Market cap $ 49.102M
Market cap (USD) $ 49.102M
P/E -2.41
PEG —
P/BV 0.48
P/S 355.81
P/OCF -3.18
P/FCF -1.05
Dividend yield —
Turnover / mcap —
Returns  
ROE -50.4%
ROI -35.9%
ROIC -29.7%
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 74.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018
Revenue — — — — 0 138K 1.48M
Net profit -71.372M -74.135M -156.087M -223.177M -156.794M -37.738M -3.109M
Free cash flow -46.619M -55.696M -102.692M -264.753M -179.969M -80.432M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018
Share price 11 19.09 7.62 0.63 17.11 — 3.64
Price performance 12m -0.42 1.51 11.1 -0.96 — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 0.00 7.55M 4.63M 2.7M 372,000
Cash and deposits (USD) 8.9M 242M 37.6M 43.7M 9.2M 8.81M 6.64M
Right-of-use assets (USD) — — 0.00 12.5M 2.39M 934,000 238,000
Cash flow detail
Operating cash flow (USD) — -29.6M -122M -180M -82M -55.7M -36.6M
Purchases of property, plant and equipment (USD) — -50.8M -57.8M -84.6M -20.7M 0.00 —
Change in payables (cash effect) (USD) — -1.05M 3.86M -1.81M -1.13M -556,000 116,000
Interest paid (cash effect) (USD) — — 0.00 -1.07M -6.64M -8M -5.04M
Share-based compensation (USD) — 1.71M 26.2M 30.4M 18.2M 17.3M 8.69M
Free cash flow (OCF - PPE - intangibles) (USD) — -80.4M -180M -265M -103M -55.7M —
Income detail
Research and development expense (USD) — 19.4M 107M 141M 39.6M 11.8M 24.7M
↳ 5y CAGR +5.0%
Total comprehensive income (USD) — -38M -157M -224M -156M -74M -71.7M
Comprehensive income to owners (USD) — -38M -157M -224M -156M -74M -71.7M
Reported May 13, 2021 Mar 7, 2022 Mar 31, 2023 Mar 31, 2023 Mar 21, 2024 Mar 4, 2025 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

DALLAS, TX, November 16, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, today reported its third quarter 2026 financial results and provided a corporate update.

Recent Highlights:

•Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates.

•Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately $67.1 million as of September 30, 2026, which Instil expects will fund its current operating plan through 2027.

August 13, 2026 at 5:00 PM EDT

PDF Version

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update.

Recent Highlights:

  • Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.

  • Cash position of approximately $69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.

Second Quarter 2026 Financial and Operating Results:

As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities of $69.9 million, which consisted of $5.5 million in cash and cash equivalents, $0.3 million in restricted cash and $64.1 million in marketable securities, compared to $76.3 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, consisting of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash, and $69.5 million in marketable securities. Instil expects that its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 will enable it to fund its operating plan beyond 2027.

In-process research and development expenses were nil for the three and six months ended June 30, 2026, compared to $10.0 million for both the three and six months ended June 30, 2025.

Research and development expenses were $0.3 million and $0.9 million for the three and six months ended June 30, 2026, respectively, compared to $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively.

General and administrative expenses were $5.1 million and $10.5 million for the three and six months ended June 30, 2026, respectively, compared to $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively.

Restructuring and impairment charges were $0.2 million and $1.2 million for the three and six months ended June 30, 2026, respectively, compared to $0.5 million and $16.6 million for three and six months ended June 30, 2025, respectively.

Net loss per share, basic and diluted were $0.63 and $1.25 for the three and six months ended June 30, 2026, respectively, compared to $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively. Non-GAAP net loss per share, basic and diluted, were $0.45 and $0.78 for the three and six months ended June 30, 2026, respectively, compared to $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

About Instil Bio

Instil Bio, Inc. is a biotechnology company focused on identifying and advancing innovative therapeutics. For more information, visit www.instilbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding pursuing potential acquisitions, in-licensing and related opportunities; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the SEC and Instil’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.

On June 11, 2026, Instil Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2026. Of the 6,781,976 shares of the Company’s common stock outstanding as of the record date, 5,757,919 shares, or approximately 84.9%, were present or represented by proxy at the Annual Meeting.

The following is a brief description of each matter voted upon and the certified results.

Proposal 1. Stockholders elected the following nominees to serve as Class II directors on the Company’s board of directors (the “Board”) until the Company’s 2029 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. The voting results for such nominees were as follows:

Director Name

Votes For

Votes Withheld Broker Non- Votes

George Matcham 3,683,114 742,925 1,331,880

Neil Gibson 3,603,901 822,138 1,331,880

Proposal 2.

Prompts

Instil Bio, Inc. (ticker TIL), listed in United States.

ETFs Holding Instil Bio, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 1,000 $ 6,240.00 Nov 12, 2026
DFAS 0.00% 6,653 $ 41.515K Nov 12, 2026
DCOR 0.00% 1,052 $ 6,564.48 Nov 12, 2026
DFAC 0.00% 1,385 $ 8,642.40 Nov 12, 2026
AVSC 0.00% 7,492 $ 43.079K Nov 16, 2026